Triatomic Management LP Zai Lab LTD Transaction History

Triatomic Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	BUY	$22.72 - $31.49 $90,880 - $125,960	4,000 Added 30.77%	17,000 $413,000
Q2 2023 Aug 14, 2023	BUY	$25.3 - $39.67 $328,900 - $515,710	13,000 New	13,000 $360,000
Q4 2022 Feb 13, 2023	SELL	$22.28 - $38.71 $710,576 - $1.23 Million	-31,893 Reduced 64.3%	17,710 $543,000
Q3 2022 Nov 14, 2022	SELL	$34.2 - $51.69 $688,514 - $1.04 Million	-20,132 Reduced 28.87%	49,603 $1.7 Million
Q2 2022 Aug 12, 2022	BUY	$23.14 - $49.68 $317,920 - $682,553	13,739 Added 24.54%	69,735 $2.42 Million
Q1 2022 May 12, 2022	BUY	$27.77 - $64.4 $805,330 - $1.87 Million	29,000 Added 107.42%	55,996 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$54.9 - $105.21 $1.48 Million - $2.84 Million	26,996 New	26,996 $1.7 Million

116

40.8M

63.1K

420K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.02B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Triatomic Management LP, based on Form 13F filings with the SEC.

Stay updated on Triatomic Management LP with notifications on news.